BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 36560675)

  • 1. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
    Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
    Afifi AM; Elgenidy A; Hashim M; Awad AK; Jalal PK
    Rev Med Virol; 2022 Nov; 32(6):e2353. PubMed ID: 35441759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
    Wu JW; Kao JH; Tseng TC
    Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
    Mak LY; Ko KL; To WP; Wong DK; Seto WK; Fung J; Yuen MF
    Gut Liver; 2020 Sep; 14(5):665-668. PubMed ID: 32457279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
    Liang LY; Wong VW; Toyoda H; Tse YK; Yip TC; Yuen BW; Tada T; Kumada T; Lee HW; Lui GC; Chan HL; Wong GL
    J Gastroenterol; 2020 Sep; 55(9):899-908. PubMed ID: 32556643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
    Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
    J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
    To WP; Mak LY; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    J Viral Hepat; 2019 Dec; 26(12):1473-1480. PubMed ID: 31418973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients.
    Zhao J; Bian D; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
    Front Cell Infect Microbiol; 2023; 13():1083912. PubMed ID: 37065191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.
    Urabe A; Imamura M; Tsuge M; Kan H; Fujino H; Fukuhara T; Masaki K; Kobayashi T; Ono A; Nakahara T; Kawaoka T; Hiramatsu A; Kawakami Y; Aikata H; Hayes CN; Maki N; Ohdan H; Chayama K
    J Gastroenterol; 2017 Mar; 52(3):366-375. PubMed ID: 27422771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
    Chang X; Li Y; Sun C; Li X; Du W; Shang Q; Song L; Long Q; Li Q; Liu H; Wang J; Yu Z; Li J; Xiao G; Li L; Chen L; Tan L; Chen Y; Yang Y
    J Gastroenterol; 2023 May; 58(5):481-493. PubMed ID: 36928343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    Hepatol Commun; 2022 Jan; 6(1):36-49. PubMed ID: 34532993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV.
    Hsieh YC; Pan MH; Jeng WJ; Hu HH; Liu J; Mizokami M; Chen CJ; Yang HI
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1303-1313.e11. PubMed ID: 35850414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B.
    Seto WK; Wong DK; Fung J; Huang FY; Liu KS; Lai CL; Yuen MF
    Clin Microbiol Infect; 2014 Nov; 20(11):1173-80. PubMed ID: 24975365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.
    Jeng WJ; Chien RN; Chen YC; Lin CL; Wu CY; Liu YC; Peng CW; Su CW; Hsu CE; Liaw YF
    Hepatology; 2024 Mar; 79(3):690-703. PubMed ID: 37625144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
    Nishida Y; Imamura M; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Aikata H; Sasaki N; Sekiguchi T; Kinukawa H; Yoshimura T; Chayama K
    J Viral Hepat; 2021 Sep; 28(9):1304-1311. PubMed ID: 34105859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Hepatol; 2016 Jul; 65(1):48-56. PubMed ID: 27034253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.